Bevacizumab and erlotinib in EGFR wild type NSCLC patients
| Author | Phase | Line of treatment | Pts | Treatment | Response rate(%) | Progression-free survival (months) | Overall survival (months) |
|---|---|---|---|---|---|---|---|
| Herbst et al. [17] | I/II | Second line | 40 | Erlotinib + Bevacizumab | 20 95% CI: 7.6-32.4% | 7.0; 1-year PFS = 38.0%, 95% CI: 24.3-59.6% | 12.6; 1-year OS = 54.2%,95% CI: 40.0%-73.4% |
| Herbst et al. [18] | II | Second line | 120 | Bevacizumab + CT | 12.5 vs. 17.9 vs. 12.2 | 4.8 vs. 4.4 vs. 3.0 HR: 0.66, 95% CI: 0.38-1.16 HR: 0.72, 95% CI: 0.42-1.23 | 12.6 vs. 13.7 vs. 8.6 HR: 0.71,95% CI: 0.41-1.21 HR: 0.78,95% CI: 0.46-1.31 |
| Herbst et al. BeTa trial [19] | III | Second line | 636 | Erlotinib + Bevacizumab vs. Erlotinib + placebo | 14 vs. 7 | 3.4 vs.1.7 HR: 0.62, 95% CI: 0.52-0.75 | 9.3 vs. 9.2 HR: 0.97, 95% CI: 0.80-1.18, P = 0.7583 |
| Wang et al. [20] | III | Second line | 297 | Erlotinib + Bevacizumab + Panitumumab vs. Erlotinib + placebo | 38 vs.15 P = 0.014 | 4.6 vs. 1.9 P = 0.003 | 10.4 vs. 8.9 P = 0.031 |
| Besse et al. BRAIN trial [21] | II | Second line | 24 | Erlotinib + Bevacizumab | 12.5 95% CI: 2.7-32.4 | 6.3 95% CI: 3.0-8.4 | 12.0 95% CI: 8.9-20.2 |
| Johnson et al. ATLAS trial [22] | III | Maintenance after I line | 745 | Erlotinib + Bevacizumab vs. Bevacizumab alone | - | 4.8 vs. 3.7, HR: 0.71, 95% CI: 0.58-0.86 P < 0.001 | 14.4 vs. 13.3 HR: 0.92, 95% CI: 0.7-1.21 P = 0.5341 |
| Dingemans et al. [23] | II | First line | 47 | Erlotinib + Bevacizumab | 25 | 3.8 (95% CI: 2.3-5.4) | 6.9 (95% CI: I 5.5-8.4) |
| Zappa et al. trial SAKK 19/05 [24] | II | First line | 101 | Erlotinib + Bevacizumab | 17.8 | 4.1 (95% CI: 2.9-5.5) | 14.1 (95% CI: 10.7-19.0) |
| Ciuleanu et al. TASK trial [25] | II | First line | 200 | Erlotinib + Bevacizumab vs. Chemo + Bevacizumab | 23.8 vs. 34.4, P = 0.19 | 18.4 vs. 25 weeks HR 2.05, 95% CI: 1.11-3.77 | 16.4 vs. n.r HR:1.24, 95% CI: 0.75-2.05 |
| Thomas et al. INNOVATIONS [26] | II | First line | 224 | Erlotinib + Bevacizumab vs. Cisplatin + Gemcitabine + Bevacizumab | 12 vs. 36, P < 0.0001 | 3.5 vs. 6.9 HR: 1.85; 95% CI:1.39-2.45 P < 0.0001 | 12.6 vs.17.8 HR: 1.41; 95% CI: 1.01-1.97 P = 0.04 |
Docetaxel or erlotinib; n.r: not reached